Johnson & Johnson: Caplyta Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study
September 22, 2026
September 22, 2026
RARITAN, New Jersey, Sept. 22 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
CAPLYTA(R) (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
CAPLYTA(R) significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3
Results build on the established efficacy, safety and . . .
* * *
CAPLYTA(R) (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
CAPLYTA(R) significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3
Results build on the established efficacy, safety and . . .